Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
08 2019
Historique:
received: 04 02 2019
revised: 09 04 2019
accepted: 07 05 2019
pubmed: 9 5 2019
medline: 6 5 2020
entrez: 9 5 2019
Statut: ppublish

Résumé

It is well known that tumour cells are dependent on communication with the tumour microenvironment. Previously, it has been shown that hypoxia (HX) induces pronounced, diverse and direct effects on cancer stem cell (CSC) qualities in different breast cancer subtypes. Here, we describe the mechanism by which HX-induced secretion influences the spreading of CSCs. Conditioned media (CM) from estrogen receptor (ER)-α-positive hypoxic breast cancer cell cultures increased the fraction of CSCs compared to normal growth conditions, as determined using sets of CSC assays and model systems. In contrast, media from ERα-negative hypoxic cell cultures instead decreased this key subpopulation of cancer cells. Further, there was a striking overrepresentation of JAK-STAT-associated cytokines in both the ERα-positive and ERα-negative linked hypoxic responses as determined by a protein screen of the CM. JAK-STAT inhibitors and knockdown experiments further supported the hypothesis that this pathway is critical for the CSC-activating and CSC-inactivating effects induced by hypoxic secretion. We also observed that the interleukin-6-JAK2-STAT3 axis was specifically central for the ERα-negative hypoxic behaviour. Our results underline the importance of considering breast cancer subtypes in treatments targeting JAK-STAT or HX-associated processes and indicate that HX is not only a confined tumour biological event, but also influences key tumour properties in widespread normoxic microenvironments.

Identifiants

pubmed: 31066211
doi: 10.1002/1878-0261.12500
pmc: PMC6670019
doi:

Substances chimiques

Culture Media, Conditioned 0
Cytokines 0
Estrogen Receptor alpha 0
Interleukin-6 0
STAT3 Transcription Factor 0
STAT3 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1693-1705

Informations de copyright

© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Références

PLoS One. 2011 Jan 13;6(1):e15313
pubmed: 21249190
Cell Cycle. 2007 Oct 1;6(19):2332-8
pubmed: 17786053
Growth Factors. 2012 Apr;30(2):88-106
pubmed: 22339650
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Nat Cell Biol. 2014 Nov;16(11):1105-17
pubmed: 25266422
J Clin Invest. 2010 Feb;120(2):485-97
pubmed: 20051626
J Clin Invest. 2007 Dec;117(12):3988-4002
pubmed: 18060036
Clin Cancer Res. 2013 Feb 1;19(3):643-56
pubmed: 23149820
J Cell Physiol. 2010 Nov;225(2):555-61
pubmed: 20506498
Curr Opin Oncol. 2014 Nov;26(6):551-5
pubmed: 25279962
Arch Biochem Biophys. 1999 Aug 1;368(1):147-55
pubmed: 10415122
Cell Cycle. 2012 Jul 15;11(14):2756-61
pubmed: 22767154
Oncogene. 2013 Jan 31;32(5):544-53
pubmed: 22469978
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7
pubmed: 19218449
Cancer Res. 2011 Jan 15;71(2):614-24
pubmed: 21224357
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Clin Chem. 2012 Dec;58(12):1682-91
pubmed: 23014600
BMC Cancer. 2018 Jun 20;18(1):674
pubmed: 29925335
Cell. 2004 Mar 19;116(6):769-78
pubmed: 15035980
Biochim Biophys Acta. 2010 Jan;1805(1):105-17
pubmed: 19931353
Cancer Discov. 2012 Sep;2(9):840-55
pubmed: 22763855
J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):111-7
pubmed: 22665270
Stem Cell Reports. 2016 Jan 12;6(1):121-36
pubmed: 26771357
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
pubmed: 21220315
Cell Cycle. 2011 Aug 1;10(15):2420-1
pubmed: 21734456
Cancer Res. 2013 Feb 15;73(4):1420-33
pubmed: 23248117
Oncotarget. 2016 Feb 9;7(6):7307-17
pubmed: 26824417
J Clin Invest. 2011 Oct;121(10):3804-9
pubmed: 21965337
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Methods. 2013 Jan;59(1):80-8
pubmed: 23021995
Nat Rev Urol. 2013 Aug;10(8):483-7
pubmed: 23752995

Auteurs

Hanna Jacobsson (H)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Hannah Harrison (H)

Breakthrough Breast Cancer Unit, Centre for Molecular Pathology, Institute of Cancer Sciences, Paterson Institute for Cancer Research, University of Manchester, UK.
Manchester Cancer Research Centre, The University of Manchester, UK.

Éamon Hughes (É)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Emma Persson (E)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Sara Rhost (S)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Paul Fitzpatrick (P)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Anna Gustafsson (A)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Daniel Andersson (D)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Pernilla Gregersson (P)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Ylva Magnusson (Y)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.

Anders Ståhlberg (A)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden.
Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden.

Göran Landberg (G)

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Sweden.
Breakthrough Breast Cancer Unit, Centre for Molecular Pathology, Institute of Cancer Sciences, Paterson Institute for Cancer Research, University of Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH